The relationship of pharmacology to side effects

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 10, 1997, Pages 55-62

  Casey, Daniel E ^a,b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE;

ANTICHOLINERGIC EFFECT; ARTICLE; COGNITIVE DEFECT; DROWSINESS; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; HUMAN; LIVER DYSFUNCTION; MENTAL DISEASE; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHOSIS; SEIZURE; SEXUAL DYSFUNCTION; TARDIVE DYSKINESIA; WEIGHT GAIN;

AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; HALOPERIDOL; HUMANS; PARKINSON DISEASE, SECONDARY; PIRENZEPINE; RECEPTORS, NEUROTRANSMITTER; SEIZURES; SLEEP; WEIGHT GAIN;

EID: 0030816278     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Deniker P. Introduction of neuroleptic chemotherapy into psychiatry. In: Ayd FJ, Blackwell B, eds. Discoveries in Biological Psychiatry. Baltimore, MD: Ayd Medical Communications; 1984:155-164
2. Casey DE. Motor and mental aspects of EPS. Int Clin Psychopharmacol 1995;10:105-114
3. Kane JM, Honigfeld G, Singer J. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
4. Snyder S, Greenberg D, Yamamura H. Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatry 1974;31:58-61
5. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
6. i values. J Pharmacol Exp Ther 1989;251:238-246
7. 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-614
8. 2 receptors. Psychopharmacol (Berl) 1993;112(1, suppl):40-54
9. Moore NA, Calligaro DO, Wong TD, et al. The pharmacology of olanzapine and other new antipsychotic agents. Current Opinion in Investigational Drugs 1993;2:281-293
10. Sanchez C, Arnt J, Dragsted N, et al. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Development and Research 1991;22:239-250
11. Saller CF, Salama AL. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacol (Berl) 1993;112:285-292
12. Casey DE. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. In: Hirsch S, Weinberger DR, eds. Schizophrenia. Oxford, England: Blackwell; 1995:546-565
13. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712-726
14. Beasley CM, Sanger W, Satterlee G, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacol (Berl) 1996;124:159-167
15. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
16. Tran PV, Dellva MA, Tollefson GD, et al. Extrapyramidal symptoms and tolerability of olanzapine vs haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997;58:205-211
17. van Kammen DP, McEvoy JP, Targum S, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacol (Berl) 1996;124:168-175
18. Daniel D, Targum S, Zimbroff D, et al. Efficacy, safety and dose response of three doses of sertindole and three doses of Haldol in schizophrenic patients. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology; December 10-15, 1995; San Juan, Puerto Rico
19. Borison RL, Arvanitis LA, Miller BG, et al. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16:158-169
20. Wetzel H, Szegedi A, Hain C, et al. Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters. Psychopharmacol (Berl) 1995;119:231-238
21. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine vs haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154:457-465
22. Beasley CM Jr, Hamilton SH, Crawford AM, et al, and The Olanzapine E003 Study Group. Olanzapine vs haloperidol: acute-phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. In press
23. Skarsfeldt T. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurons in rats: acute and repeated treatment. Synapse 1992;10:25-33
24. Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic. Neuropsychopharmacol 1996;14:97-104
25. Goldstein JM. Preclinical profile of Seroquel (quetiapine): an atypical antipsychotic with clozapine-like pharmacology. In: Holliday SG, Ancill RJ, MacEwan GW, eds. Schizophrenia: Breaking Down the Barriers. New York, NY: John Wiley & Sons; 1996:177-208
26. Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia. JAMA 1991;266:2402-2406
27. Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacol (Berl) 1989;99(suppl):47-53
28. Street JS, Tamura RN, Sanger TM, et al. Long-term treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol. In: New Research Program and Abstracts of the Annual Meeting of the American Psychiatric Association. New York, NY; May 8, 1996; Abstract NR605:235
29. Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991;41:369-371
30. Reddig S, Minnema AM, Tandon R. Neuroleptic malignant syndrome and clozapine. Ann Clin Psychiatry 1993;5:25-27
31. Webster P, Wijerame C. Risperidone-induced neuroleptic malignant syndrome. Lancet 1994;344:1228-1229
32. Lee H, Ryan J, Mullett G, et al. Neuroleptic malignant syndrome associated with the use of risperidone, an atypical antipsychotic agent. Human Psychopharmacology 1994;9:303-305